查找临床试验
已按「系统性红斑狼疮」检索，对应国际通用词 systemic lupus erythematosus
共找到 12 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 10:03，每 5 分钟自动同步Chinese Rheumatism Biobank(CRB)
China
年龄 不限 – 不限
Chinese SLE Treatment And Research Group
Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus
China
年龄 18 Years – 75 Years
Excyte Biopharma Ltd
Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
China
年龄 18 Years – 70 Years
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
China
年龄 18 Years – 70 Years
Changhai Hospital
A Study of Telitacicept in Lupus Nephritis
China
年龄 18 Years – 75 Years
RemeGen Co., Ltd.
The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
China
年龄 18 Years – 65 Years
Nanjing University School of Medicine
Long-Term Outcomes in SLE at Peking University People's Hospital
China
年龄 18 Years – 不限
Peking University People's Hospital
A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus
China
年龄 18 Years – 65 Years
Guangdong Hengrui Pharmaceutical Co., Ltd
NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis
China
年龄 18 Years – 65 Years
Guangdong Provincial People's Hospital
Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE
China
年龄 18 Years – 不限
Chongqing Precision Biotech Co., Ltd
Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
China
年龄 18 Years – 65 Years
Second Affiliated Hospital, Zhejiang University, School of Medicine
the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
China
年龄 18 Years – 65 Years
Tongji Hospital